Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116909 · ClinicalTrials.gov registry record · Phase 2
A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy
A Phase 2 study of Locally Recurrent or Metastatic Cancer of the Head and Neck and Must Have Failed First-Line Therapy, sponsored by OSI Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
- 4
- Study locations
NCT00116909: Completed Phase 2 study of Locally Recurrent or Metastatic Cancer of the Head and Neck and Must Have Failed First-Line Therapy, sponsored by OSI Pharmaceuticals.
NCT00116909 is a Phase 2 study of Locally Recurrent or Metastatic Cancer of the Head and Neck and Must Have Failed First-Line Therapy that has completed, run by OSI Pharmaceuticals. The registered enrollment target is 85 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00116909, a Phase 2 study of Locally Recurrent or Metastatic Cancer of the Head and Neck and Must Have Failed First-Line Therapy, has completed, sponsored by OSI Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
- 4
- Study locations
Study Summary
Multi-center, Phase II study to evaluate the efficacy and safety of OSI-7904Lin head and neck cancer in patients who have failed first-line therapy
Conditions Studied
Interventions
- DRUG OSI 7904L
Study Locations (4)
Tennessee
- Sarah Cannon Cancer Center - Nashville
- The Vanderbilt Cancer Center - Nashville
Massachusetts
- Dana-Farber Cancer Institute - Boston
New York
- Stony Brook University Hospital - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
What the finished NCT00116909 record still lists
NCT00116909 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 85 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (36% lower).
The record links to 2 conditions, with Locally Recurrent or Metastatic Cancer of the Head and Neck appearing as the primary indexed condition, and to 1 intervention - of which OSI 7904L is the first listed.
NCT00116909 reports a single indexed study location in Tennessee, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT00116909 about?
NCT00116909 is a clinical study titled "A Study of OSI-7904L as Treatment in Patients With Head and Neck Cancer Who Have Failed First-Line Therapy". Multi-center, Phase II study to evaluate the efficacy and safety of OSI-7904Lin head and neck cancer in patients who have failed first-line therapy
What is the current status of trial NCT00116909?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2004-08. Estimated completion is 2005-08.
What conditions does trial NCT00116909 study?
This clinical trial studies the following conditions: Locally Recurrent or Metastatic Cancer of the Head and Neck, Must Have Failed First-Line Therapy.
What interventions are being tested in trial NCT00116909?
The interventions under investigation include: OSI 7904L (DRUG).
Who is sponsoring clinical trial NCT00116909?
This trial is sponsored by OSI Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00116909 being conducted?
This trial has 4 study locations across Massachusetts, New York, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00116909's enrollment target sits among peer trials
85 820th of 2000 higher than 1,179 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00842283 · 85 participants
Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target
- NCT02133196 · 85 participants · Phase 2
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
- NCT03823144 · 85 participants · NA
Intravital Microscopy in Human Solid Tumors
- NCT03875638 · 85 participants · Phase 2
Treating Hyperexcitability in AD With Levetiracetam
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia